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Abstract
Parathyroid hormone (PTH) is a key factor in bone metabolism, able to stimulate
both osteoblasts to cause bone formation and osteoclasts to cause bone resorption.
The studies presented herein set forth to examine both the formative and resorptive
pathways in light of a newly discovered inhibitory factor, serum amyloid a3 (Saa3).
Saa3 is particularly germane to the PTH signaling pathway as it is secreted by cells of
the osteoclast lineage in response to PTH stimulation of prostaglandin. Saa3 then
enacts its inhibitory effects by acting back onto osteoblasts to inhibit PTH’s ability to
stimulate cAMP/PKA signaling. In the absence of Saa3 we have observed that PTH is
able to stimulate the phosphorylation of β-catenin at two novel sites, serine 552 and
serine 675. These sites represent a cAMP/PKA dependent mechanism by which βcatenin signaling may be stimulated outside the dogma of canonical wnt signaling. Our
data suggest that PTH phosphorylation of these sites increases β-catenin signaling as
measured by TCF/LEF activity and downstream gene expression, and that the inclusion
of Saa3 into these conditions completely ablates this pathway. PTH is also known to
stimulate receptor activator of nuclear kappa-b ligand (RANKL) expression by
osteoblasts via cAMP/PKA. As a potent stimulator of osteoclastogenesis we were then
interested to examine the effects of the cAMP inhibitor, Saa3, upon PTH stimulation of
RANKL. Interestingly, we discovered that PTH stimulation of RANKL was not only
unaffected by inhibition of the cAMP/PKA pathway, but that antagonists of the Ca2+/PKC
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pathway were able to prevent PTH stimulation of RANKL even in the presence of a
robust cAMP response to PTH. We then conclude that the anabolic portions of the PTH
pathway are mediated through cAMP/PKA and the catabolic portions are mediated
through Ca2+/PKC. This dichotomy explains how the catabolic effects of PTH are more
visible and pronounced as they go unhindered by the inherent Saa3 negative feedback
loop which renders the anabolic effects invisible in basal conditions.
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1. Introduction

1.1 Bone Homeostasis: Osteoblasts and Osteoclasts
Bone homeostasis is regulated by two cell types: osteoblasts, which form bone, and
osteoclasts, which resorb bone. During development, bone grows by the process of
modeling, in which resorption and formation can occur independently. In adults, the
bone remodeling cycle—bone resorption followed by bone formation—determines the
maintenance of bone mass. This cycle is known as bone turnover. An imbalance or
uncoupling of this cycle, resulting in resorption being greater than formation, causes
bone loss. Hence, much of our attempts to treat or prevent osteoporosis center on
trying to manipulate the bone remodeling cycle. .
Osteoblasts are differentiated from mesenchymal precursor cells (1). Once cells are
committed to the osteoblastic lineage, they can differentiate into mature osteoblasts,
which secrete matrix that can be subsequently mineralized to form bone. Active
osteoblasts subsequently become quiescent cells lining the mineralized matrix, but they
may be reactivated to form new matrix by certain agents or to uncover the mineralized
matrix to allow resorption. The terminal cell of the osteoblast lineage is the osteocyte.
Osteocytes are non-replicating cells that reside within the mineralized matrix. They are
connected to each other and to cells on the surface by an extensive network of dendritic
outgrowths through small channels called canaliculi. The osteocyte is thought to be the
cell that senses and communicates mechanical strain. Recent studies suggest that the
osteocyte is also important in mediating the regulation of the bone turnover cycle.
Osteoclasts are multinucleated cells of the hematopoietic lineage able to resorb
mineralized tissue (2). Formation and differentiation of osteoclasts from hematopoietic
1

precursor cells requires two factors: 1) macrophage colony-stimulating factor (M-CSF)
and 2) receptor activator of nuclear kappa-b ligand (RANKL). When exposed to these
two factors osteoclast precursors proliferate and fuse into mature osteoclasts. Mature
osteoclasts can then initiate resorption by first eroding the inorganic components of the
bone in a process known as demineralization. This phase is followed by degradation of
the organic components, primary the type I collagen matrix. Osteoclasts achieve this
resorption by creating an isolated acidic environment between their cellular membrane
and where it attaches to the bone surface. Hallmarks of this process include a ruffled
membrane morphology as well as pits of resorption left behind on the bone surface.
Osteoblasts and osteoclasts are not merely linked by their opposing actions on bone
metabolism, but have a direct connection via RANKL. RANKL expressed by
osteoblasts is able to stimulate osteoclasts through its receptor RANK, and RANK
signaling is directly responsible for osteoclastogenesis. RANKL is expressed by several
cell types, but seems to require cell-cell contact despite there being a soluble form,
relegating RANKL to local action only (3, 4). In fact, RANKL membrane shedding has
been shown to decrease osteoclastogenesis (5). Osteoblasts can also secrete
osteoprogeterin, a decoy receptor for RANKL, in order to antagonize RANKL stimulated
osteoclastogenesis. Parathyroid hormone (PTH) is able to stimulate both resorption
and formation by stimulating the differentiation of osteoblasts and their subsequent
RANKL expression – causing the differentiation of osteoclasts. Diseases such as
osteoporosis and osteitis fibrosa are direct symptoms of an imbalance in formation and
resorption rates of these cells, in some cases these diseases result from pathological
conditions affecting physiological levels of PTH (6-8).
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1.2 Parathyroid Hormone
PTH is an eighty-four amino acid long peptide produced in the parathyroid by chief
cells (9, 10). PTH maintains physiological levels of calcium within the blood by regulating
bone resorption and formation, increasing 1,25(OH)vitamin D3 production in the kidney,
and by regulating Ca++ reabsorption. PTH acts via a G-protein coupled receptor called
PTH1R that is highly expressed by osteoblasts and in the kidney. The intracellular
signaling pathways activated via the PTH1R receptor include Gs-mediated activation of
adenylate cyclase, resulting in cAMP production and protein kinase A (PKA) activation,
and Gq/11-mediated phospholipase-C-β (PLCβ) stimulation, leading to inositol 1,4,5trisphosphate (IP3) production, calcium mobilization, and protein kinase C (PKC)
activation (11, 12). PTH can act anabolically on bone by modulating osteoblast
proliferation, differentiation, and survival, (13, 14); and catabolically, by promoting
osteoclast formation via osteoblastic RANKL expression

(15, 16).

The anabolic and

catabolic effects can be induced by intermittent or continuous treatment, respectively
(17).

Studies have indicated that the anabolic effects of PTH occur largely through the
cAMP signaling pathway (12, 18). In order to stimulate cAMP production, PTH binds to its
receptor, and in turn releases Gαs. Gαs then travels to the transmembrane protein
adenylate cyclase (AC). Once bound, AC is able to catalyze the transition of adenosine
triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Binding of cAMP to
the regulatory subunits of the tetramer PKA allows the catalytic subunits to
phosphorylate downstream proteins such as cAMP response element-binding protein
(CREB) in order to affect transcription directly or indirectly via nuclear translocation.

3

Alternatively, cAMP can then activate the guanine exchange factor exchange protein
directly activated by cAMP (EPAC). EPAC, in turn, converts the GDP bound to the
GTPase Ras-related protein (Rap) to GTP. Rap is then able to bind to the kinase BRaf, which in turn signals through the mitogen activated kinase MEK/extracellular
signal-regulated kinase (ERK) pathway to affect a host of cellular responses including:
survival, proliferation, and differentiation

(19-21).

Two modes of PTH receptor activation exist: 1) a short-term activation of the
receptor and 2) sustained activity of the receptor caused by receptor internalization

(22).

Sustained activity occurs contrary to canonical GPCR signaling–in which internalization
of the GPCR prevents additional receptor activation from occurring. In sustained
activity the PTH receptor continues to stimulate sustained levels of cAMP production
once internalized in an endosomal compartment containing PTH, G-protein subunits,
and adenylate cyclase (23, 24).

1.3 Cyclooxygenase-2
PTH can also induce expression of COX-2 in osteoblasts (25-27). COX-2 is an
isozyme of the cyclooxygenase family which contains two members: COX-1 and COX2. COX-1 is constitutively expressed, while COX-2 expression is inducible (28). Rate
limiting COX enzymes catalyze the cyclooxygenase reaction that converts arachidonic
acid into prostaglandin G2 (PGG2) via a cyclooxygenase reaction, and further into
prostaglandin H2 (PGH2) via a peroxidase reaction (29). PGH2 is the major precursor of
several bioactive proteins, most notably in osteoblasts: prostaglandin E 2 (PGE2) (25, 30).

4

In vivo studies in our lab show that basal concentrations of cAMP within the plasma
of COX-2 KO mice are higher than in WT mice, implicating COX-2 as a factor that
causes inhibition of cAMP production (31).

1.4 Wnt/β-catenin Signaling
The members of the Wnt family of glycoproteins are typically 350-400 amino acids
long. Their secretion accompanies effects upon many developmental processes
including cell fate determination, cell polarity, limb patterning, proliferation, and
migration (32, 33). In addition, they are highly conserved across species and primarily
affect cells through β-catenin dependent and independent pathways. The β-catenin
dependent pathway is commonly referred to as the canonical pathway and involves a
Wnt protein binding to a dimer comprised of isomers of the proteins frizzled (Fz) and
low-density lipoprotein receptor-related protein (LRP). Once this binding occurs, the
protein disheveled (Dsh) is activated. At resting state, β-catenin is quickly degraded via
ubiquitinylation mediated by a destruction complex comprised of several proteins:
Glycogen synthase kinase 3 beta (GSK3-β), Axin, and Adenomatous polyposis coli
(APC). Once activated by Wnt-Fz-LRP interaction, Dsh inhibits GSK3-β from marking
β-catenin for destruction. Following inhibition of the destruction complex, β-catenin
accumulates in the nucleus where it acts to regulate TCF/LEF family transcription
factors. These factors can target a wide variety of genes that in turn affect cell fate,
survival, and proliferation (34).
β-catenin is marked for destruction and stabilization by a hyper- and
hypophosphorylated state, respectively. The destruction complex phosphorylates β-
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catenin first on Ser45 via casein kinase 1 (CK1) action; resulting in phosphorylation of
Thr41, Ser33, and Ser37. This hyperphosphorylation marks β-catenin for
ubiquitinylation by βTrcp to be proteasomally degraded. Conversely, when β-catenin is
in its hypophosphorylated state, characterized by phosphorylation on either Ser552 or
Ser675 or both, it is marked for stabilization and translocation to the nucleus. This is
(35-38).

mediated by protein kinases including PKA and Akt, the former specific to Ser675

Wnt signaling that occurs independent of β-catenin is designated non-canonical
signaling and can occur via several pathways including the Wnt/calcium pathway, the
heterotrimeric GTP-binding protein pathway, and the planar cell polarity pathway (PCP)
(34).

1.5 PTH modulates the Wnt signaling pathway via cAMP/PKA activation
Synthetic segments of PTH able to affect the cAMP/PKA pathway also increased
expression of several Wnt signaling components including β-catenin, LRP-6, and Fz-1
when given continuously. In addition, decreases in LRP-5 and Dkk1, an LRP-6 inhibitory
ligand, were also seen (39, 40). Both intermittent PTH treatment, as well as cAMPdependent PKA activity were shown to inactivate GSK3-β via phosphorylation (18, 41).
This suggests that the PKA activity upon GSK-3-β can be mediated by PTH, which is
coupled directly to PKA via the PTH receptor. PTH receptor was also found to directly
bind Dsh in order to stimulate β-catenin signaling independent of Wnts and LRPs

(16).

Constitutively active GSK-3-β abolishes TCF-dependent transactivation by forskolin.
This affect was shown to be receptor independent as Dkk1 overexpression to outcompete LRP activation could not abolish forskolin mediated transcriptional regulation
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of RANKL (18). Additionally, Dkk1 was found to inhibit PTH stimulated cAMP production
(42).

It seems then that the canonical Wnt signaling pathway is inhibitory for RANKL

expression as further studies focusing on models treated with Wnt3a or overexpressing
β-catenin showed a decrease in PTH stimulated RANKL expression and the opposite
was seen in models featuring Dkk1 treatment or the ablation of β-catenin expression (4346).

A novel PKA-dependent pathway in which PTH recapitulates the actions of Wnt
ligands on LRP6 by forming a ternary complex with both its receptor and LRP6 has
been observed (47). LRP6’s intracellular domain is comprised of five PPSP motifs
accompanied by CK1 sites. These motifs can be phosphorylated by PKA, GSK3-β,
and CK1 (48, 49). LRP6 becomes able to recruit Axin away from the destruction complex
once phosphorylated; thereby, preventing it from marking β-catenin for degradation.
While typically LRP6 activation is seen in regard to the Wnt signaling pathway, it has
also been shown that PTH is able to not only cause phosphorylation of LRP6 at the
PPSP motif corresponding to Ser1490, but form a ternary complex including PTH,
PTH1R, and LRP6 (47). This effect was shown to be dependent upon PKA, and specific
to LRP6, as the same phenomena was not seen with LRP5 stimulated with PTH and
forskolin, an adenylate cyclase agonist. This fits well with previous findings that LRP5
deficiency in mice did not inhibit the anabolic effects of PTH upon bone

(50, 51).

Additionally, continuous PTH activity has been shown to down-regulate mRNA
expression of LRP5 while up-regulating that of LRP6 both in vitro and in vivo (39).

1.6 PTH and RANKL
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An essential component of the pathway by which PTH affects bone homeostasis is
RANKL. Expressed by osteoblasts to stimulate osteoclastogenesis, RANKL has been
traditionally thought to be stimulated by PTH via cAMP/PKA activation

(52, 53).

This

notion is reinforced by the existence of several regulatory cAMP response elements
upstream of the RANKL gene that control its expression

(54, 55).

Further evidence of the

importance of the PTH/cAMP/PKA/RANKL interaction to bone homeostasis was seen
when this region was deleted in mice, resulting in increased bone mass and a reduction
in RANKL expression response to PTH treatment (56). However, alternative evidence
points to a more complex interaction underlying PTH stimulation of RANKL.
PKA activation within mesenchymal stem cells was shown to decrease the
RANKL/OPG ratio (57). Further, in mice lacking the receptor for oncostatin M cAMP
response to PTH was unchanged while RANKL response was sustained, causing a
catabolic resorption response to a normally anabolic PTH treatment modality; certainly
suggesting that cAMP is not the only regulator of PTH/RANKL interaction

(8).

While

previously shown that exhaustion of the PKC response system via pretreatment of PKCagonist PMA has no effect on PTH’s ability to stimulate RANKL expression, an
alternative study has shown that both PMA and ionomycin are capable of increasing
RANKL expression pointing to involvement of both PKC and calcium in the RANKL
pathway (53, 58). Both the involvement of PKA and PKC in the regulation of PTH
stimulated RANKL expression was also shown when inhibitors of each pathway blunted
the RANKL response to PTH (59). Moreover, it has been hypothesized that downstream
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of PTH activation of the calcium/PKC pathway is activation of MEK/ERK, since inhibitors
of both calcium and PKC signaling prevented ERK activation in osteoblasts

(60).

Additionally, PTH effects upon RANKL expression and osteoclastogenesis are
dependent upon prostaglandins. PTH stimulation of RANKL gene expression by
osteoblasts was decreased in COX-2 KO osteoblast/osteoclast co-cultures resulting in
decreased osteoclast formation (61). Similar results were seen in co-cultures lacking
EP2, the receptor for PGE2 (62). However, once again, prostaglandins do not represent
the whole story as NSAID treatment blocked lipopolysaccharide induced PGE2
inhibition of OPG expression, but not that of RANKL

(63).

Alternate studies have also

shown that PTH is able to increase RANKL expression and decrease that of OPG
despite the presence or absence of either EP2 or EP4

(64).

Independent of PGE2, PTH

analogs unable to stimulate cAMP production do not decrease OPG expression, but
maintain their ability to stimulate RANKL (65).
In vivo evidence of the calcium and PKC pathway was shown when a low calcium
diet given to mice with a mutation preventing PTHR activation of PLC, an important
upstream event in the PKC cascade. These mice showed attenuated bone formation in
response to PTH when compared to WT mice (66). Further, the PKC pathway seems to
be important downstream of RANKL. The PKC inhibitor GF109203 blocks
osteoclastogenesis and osteoclast activity and osteoclastic gene expression in RANKL
treated bone marrow cultures (67). It has been hypothesized that the pathway
downstream of RANKL focuses on PKC-β’s ability to inactivate GSK-3β allowing
NFATc1 to induce osteoclastic gene expression (68). This hypothesis was supported by
RANKL induced bone resorption in calvaria being decreased by PKC-β inhibition (68).

9

1.7 PTH and Serum Amyloid A3

Observations regarding the interaction between PTH and PGE2 revealed that in the
absence of COX-2, the enzyme responsible for PGE2 production, the typical catabolic
response expected during continuous PTH treatment was absent. In fact it was
observed that in vivo continuous PTH infusion became anabolic and the anabolic effect
of intermittent PTH treatment was increased in COX2 null mice (69). Results from these
in vivo are summarized in Figure 1. Evidence for the anabolic effects of PTH in Cox2
KO mice can be seen in elevated levels of P1NP in the serum (Fig. 1a), increases in
osteoblast surface (Fig. 1g), ultimately culminating in an increase in femoral bone
marrow density and volume (Fig. 1c-d). However, measures of bone resorption were
similarly increased in both Cox2 KO and WT mice treated with PTH: serum CTX (Fig.
1b), osteoclast surface (Fig. 1h), and RANKL/OPG mRNA expression (Fig. 1e-f).
Ultimately, this revealed a pathway by which Cox2 acts to antagonize the anabolic
effects of PTH while leaving the catabolic response intact.
In vitro studies revealed that the PTH/PGE2 negative feedback loop required action
by bone marrow macrophages (BMMs) stimulated down the osteoclast lineage by
RANKL (70). Ultimately this negative feedback loop was determined to be due to serum
amyloid a3 (Saa3) secreted by osteoclast precursors in response to PTH stimulated
PGE2 production by osteoblasts (71). Once secreted, Saa3 acts back onto the N-formyl
peptide receptor 2 (Fpr2) expressed by osteoblasts to inhibit the ability of PTH to
stimulate cAMP production in a Gαi/o dependent manner (71).
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Saa3 is an apolipoprotein which experiences acute and dramatic increases in its
circulatory expression during inflammation

(72-74).

In mice, Saa3 is the only member of

the serum amyloid a family to be expressed in extra-hepatic tissues; Saa1 and Saa2
expression is confined to the liver (74-77). Serum amyloids play roles in several diseases
associated with inflammation, including: rheumatoid arthritis, atherosclerosis, obesity,
cancer metastasis, and amyloidosis (77-79). In addition, Saa3 is expressed during the
osteoblast-osteocyte differentiation stage and stimulates osteoclastic differentiation

(80).

1.8 Specific Aims

Aim 1: Use COX-2 KO mice to investigate the actions of PTH on the Wnt signaling
pathway in a system lacking Saa3. We hypothesize that conditioned medium
containing Saa3 will inhibit PTH’s actions on the Wnt signaling pathway.

1A: Determine if PTH stimulated β-catenin phosphorylation and gene expression
are mediated by the cAMP/PKA pathway

1B: Determine if conditioned medium containing Saa3 inhibits PTH-stimulated wnt
target gene transcription.

Aim 2: Utilize Saa3 as a cAMP inhibitor to investigate the role of cAMP signaling in
PTH stimulated RANKL expression. We hypothesize that PTH stimulated RANKL

11

expression acts via the PKC pathway and not the cAMP/PKA pathway in our model
system.

2A: Determine the role of calcium and PKC in PTH stimulated RANKL expression in
a system that cannot respond to PTH via cAMP.

2B: Determine the role of ERK signaling in the PTH/RANKL pathway.

12

A

B

C

D

E

F

G

H

Fig. 1. Skeletal response of Cox2 KO and WT mice after 12 days of PTH infusion
(40 μg/kg/d). (A) serum marker of formation, P1NP, (B) serum marker of resorption,
CTX, (C) Femoral BMD % change measured in vivo at beginning and end of infusion,
(D) μCT morphometric analysis of femoral BV/TV, (E) tibial OPG mRNA expression, (F)
tibial Rankl mRNA expression, (G) histomorphometric analysis of femoral Obs./BS, (H)
histomorphometric analysis of femoral Ocs./BS. Bars are means ± SEM for 7 WT and 7
KO mice treated with vehicle and 8 WT and 8 KO mice treated with PTH. a Significant
effect of PTH, p<0.01. b Significant effect of genotype, p<0.01.

13

2. Inhibition of PTH-stimulated β-catenin signaling in osteoblasts by bone marrow
macrophages
2.1 Abstract
Bone marrow macrophages (BMMs), in the presence of cyclooxygenase-2 (Cox2)
produce PGE2, and secrete an inhibitory factor in response to Rankl that blocks PTHstimulated osteoblastic differentiation. The goal of this study was to determine if the
inhibitory factor also blocks PTH-stimulated Wnt signaling. Primary calvarial osteoblasts
(POBs) were co-cultured with conditioned medium (CM) from Rankl-treated wild type
(WT) BMMs, which make the inhibitory factor, and Cox2 knockout (KO) BMMs, which
do not. PTH induced cAMP production was blocked by WT CM but not by KO CM. In
the presence of KO CM, PTH induced phosphorylation at -catenin serine sites, ser552
and ser675, previously shown to be phosphorylated by protein kinase A (PKA).
Phosphorylation was blocked by WT CM and by H89, a PKA inhibitor. PTH did not
increase total -catenin. PTH-stimulated transcription factor/lymphoid enhancer-binding
factor response element activity in POBs was blocked by WT CM and by serum amyloid
A (SAA), the human recombinant analog of murine Saa3, which has recently been
proposed to be the inhibitory factor. In POBs cultured with Cox2 KO CM, PTH
increased expression of multiple genes associated with the anabolic actions of PTH and
decreased expression of Wnt antagonists. This differential regulation of gene
expression was not seen in POBs cultured with WT CM. These data highlight the ability
of PTH to phosphorylate -catenin directly via PKA and demonstrate the ability of a
Cox2-dependent inhibitory factor, secreted by preosteoclasts, to abrogate PTH
14

stimulated -catenin signaling. Our results suggest that PTH can stimulate a novel
negative feedback of its anabolic actions by stimulating Rankl and Cox2 expression.

Key Words: Wnt genes, serine 552/675, cyclooxygenase-2, serum amyloid A, protein
kinase A, cAMP
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2.2 Introduction
Parathyroid hormone (PTH) is a potent regulator of bone homeostasis–able to
stimulate both bone formation and resorption by stimulating the differentiation of both
osteoblast and osteoclast populations (81, 82). Intermittent therapy with human 1-34 PTH
(teriparatide) was the first FDA approved anabolic therapy for osteoporosis

(83).

In

contrast, continuous PTH administration or elevation has been shown to cause bone
loss (82). PTH acts via its receptor PTH1R, a G-protein coupled receptor that is highly
expressed by osteoblasts and that activates both Gαs and Gαi signaling pathways (84).
Gαs activates adenylyl cyclase resulting in cAMP production and protein kinase A (PKA)
activation, while Gαi leads to activation of protein kinase C (PKC) and release of Ca2+.
The anabolic effects of PTH are thought to be mediated via Gα s (12, 85).
PTH is also known to increase the expression of cyclooxygenase 2 (Cox2), an
inducible enzyme responsible for acute production of prostaglandin E 2 (PGE2), and
PGE2 can also stimulate both bone formation and resorption

(25, 26, 86, 87).

In vitro studies

have shown that PTH can stimulate osteoblast differentiation in Cox2 KO bone marrow
stromal cells (BMSCs) but not in WT BMSCs (70). In these studies, PGE2, produced
either by Cox2 in osteoblasts or Cox2 in BMMs, acted via the EP4 receptor to cause
bone marrow macrophages (BMMs), committed to the osteoclastic lineage by Rankl, to
secrete a factor that inhibited the PTH stimulation of osteoblastic differentiation (70). In
vivo studies showed there was a greater anabolic effect of intermittent PTH in Cox2 KO
mice compared to WT mice (31). When PTH was administered continuously by infusion
to WT mice, it was catabolic as expected. In contrast, PTH was markedly anabolic in
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KO mice (69). The inhibitory factor produced by the BMMs has recently been proposed
to be serum amyloid A3 (Saa3) (71).
cAMP-dependent PKA has been shown to cause the phosphorylation of β-catenin at
two distinct sites: serine 552 (Ser552) and serine 675 (Ser675)

(36, 37).

These sites have

been linked to increases in β-catenin mediated transcriptional activity. Traditionally, βcatenin has been linked with osteoblast differentiation via the canonical Wnt pathway, in
which Wnt agonists act via Lrp5/6 and Frizzled receptors/co-receptors on the β-catenindestruction-complex to prevent the ubiquitination and proteolysis of β-catenin (88). The
cAMP/PKA pathway provides for a novel Wnt-independent mechanism in which βcatenin proteins are acted upon directly to increase their signaling efficacy. PTH
signaling has recently been shown to phosphorylate β-catenin at Ser552 in a cAMPdependent manner and to increase the downstream transcriptional activity of β-catenin
via this pathway (89).
The goal of the current study was to investigate the effects of the Cox2-dependent
inhibitor on PTH-stimulated β-catenin signaling. We cultured POBs with conditioned
medium (CM) from Rankl-treated WT BMMs, which produce the inhibitor, and Cox2 KO
BMMs, which do not. Using this model we demonstrated that PTH stimulation of (1)
phosphorylation of β-catenin at Ser552/675, (2) β-catenin transcriptional activity and (3)
expression of genes thought to mediate osteoblast differentiation were blocked by the
Cox2/PGE2-dependent inhibitor produced by Rankl-stimulated BMMs.

2.3 Materials and Methods
2.3.1 Materials
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Bovine PTH (bPTH; 1-34) was obtained from Sigma-Aldrich (St. Louis, MO).
Forskolin (cAMP agonist), H-89 (PKA inhibitor) and GF109203X (PKC inhibitor) were
obtained from Enzo Life Sciences (Farmingdale, NY). Human recombinant SAA (ApoSAA), which corresponds to human Apo-SAA1α, except for the presence of an Nterminal methionine and two substituted residues present in Apo-SAA2β, was
purchased from PeproTech (Rocky Hill, NJ). Antibody for Actin C-11 (sc-1615) was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for phospho-βcatenin Ser552 (#9566), phospho-β-catenin Ser675 (#9567), phospho-β-catenin
Ser33/37/Thr41 (#9561), and amino terminal β-catenin (#9581) were obtained from Cell
Signaling Technology (Danvers, MA).

2.3.2 Animals
Mice that produce non-functional Cox2 protein, due to disruption of Ptgs2 in a
C57BL/6, 129SV background, which we call Cox2 KO mice, were the gift of Scott
Morham (30). Cox2 KO mice were backcrossed into the outbred CD-1 background (31).
Following 20 generations of backcrossing, the Cox2 KO mice no longer developed
either renal failure or female infertility (31). Maintenance colonies heterozygous for the
Cox2 gene disruption were refreshed twice a year with WT mice from Jackson
Laboratory (Bar Harbor, ME) to prevent genetic drift. Mice are genotyped as described
previously, and experimental mice are bred by WT x WT or KO x KO mating

(31).

Animal

studies were performed in compliance with protocols approved by the Animal Care and
Use Committee of UConn Health.
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2.3.3 Cell Culture
All cell cultures were grown in humidified incubation conditions of 5% CO2 at 37°C.
Basic medium was 10% heat inactivated fetal calf serum (HIFCS), 100 U/mL penicillin,
and 50 µg/mL streptomycin in α-MEM (Invitrogen, Carlsbad, CA). Osteoblast
differentiation medium was basic media supplemented with 50 µg/mL
phosphoascorbate. Treatment vehicles were the following: 0.001 N hydrochloric acidacidified 0.1% bovine serum albumin (BSA) in 1x phosphate buffered saline (PBS) for
PTH; 0.1% BSA in 1x PBS for osteoprotegerin (OPG), macrophage colony stimulating
factor (M-CSF), and receptor activator of nuclear factor κ-B ligand (Rankl); and dimethyl
sulfoxide (DMSO) for isobutyl methyl xanthine (IBMX), H-89, GF109203X, and forskolin.

2.3.4 Primary Osteoblasts (POBs)
POBs were harvested from calvariae of neonatal mice. Sutures were removed and
the calvariae were minced, washed multiple times with 1x PBS, and subsequently
digested with 0.5 mg/mL collagenase P (Roche Diagnostics, Indianapolis, IN)
solubilized in 1 mL trypsin/EDTA and 4 mL PBS at 37°C. Four 10 minute digests were
performed followed by a fifth and final digest for 90 minutes. After each digest the
reaction was halted by the addition of 10% HIFCS. Cells from digests 2-5 were
collected, filtered through a Nitex membrane (Millipore, Bedford, MA), and plated at a
density of 50,000 cells/well in 6-well cell culture plates in differentiation medium.
Medium was changed every three days. We used only freshly plated cells for all
experiments.
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2.3.5 Culture of Conditioned Medium (CM) with POBs
CM was collected from BMM cultures, centrifuged for 5 minutes at 800 rpm at 4°C to
remove debris and frozen for later use. BMMs were cultured following the Faccio
protocol: http://www.orthoresearch.wustl.edu/content/Laboratories/2978/RobertaFaccio/Faccio-Lab/Protocols.aspx. BMMs were obtained from 8 week old mice. In
brief, nucleated bone marrow cells were plated in 150 mm petri dishes (Fisher Scientific,
Pittsburgh, PA) at a density of 1 x 107 cells/dish in basic media, supplemented with 100
ng/mL M-CSF. Cultures were expanded twice for three days each. Following
expansion, BMMs were re-plated in 12-well cell culture plates at a density of 6 x 104
cells/well in basic media and treated with M-CSF and Rankl (both at 30 ng/mL). CM was
collected after 3 days of culture, a day before tartrate resistant acid phosphatase
positive multinucleated cells formed in the BMM cultures. CM was added to Cox2 KO
POBs 2 hours before agonist treatment at a concentration of 3 parts CM to 1 part
differentiation media. The only exception was for the study of differentiation, where
treatments with agonists and CM were begun at the time of plating and continued for
the entire 14 day period. Unless noted otherwise, all cultures were treated with 50
ng/mL OPG to prevent Rankl in the CM or PTH-stimulated Rankl in the POBs from
inducing any remaining hematopoietic cells in the POB cultures from becoming
osteoclasts and making more of the inhibitory factor (70).

2.3.6 Intracellular cAMP Measurement
On day five of culture, Cox2 KO POBs were treated with 3 parts WT or KO CM and
1 part differentiation media for 2 hours, followed by 0.5 mM IBMX for 45 minutes, and
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PTH (10 nM) and FSK (10 µM) for 15 minutes. For extraction, 400 µL of ice-cold ethanol
was added to each well and the cultures were detached from the plate by scraping and
collected in 1.5 mL centrifuge tubes. Samples were then centrifuged at 1500 x g for 10
minutes at 4°C. The supernatant was collected and lyophilized and cAMP
concentration was determined using an enzyme immunoassay kit (Cayman Chemical,
Ann Arbor, MI).

2.3.7 Western Blotting
Proteins were extracted from culture by the addition of lysis buffer (2% SDS, 10 %
glycerol, 62 mM Tris, pH: 6.85) and quantified using the BCA protein assay kit (Pierce,
Rockford, IL). 10% SDS –PAGE was used to separate 15 µg of total protein, prior to
transfer onto a nitrocellulose membrane. Membranes were washed with 1x Trisbuffered saline (TBS, pH: 7.6), blocked in blocking buffer (0.1% Tween-20, 5% (w/v)
non-fat dry milk, 1x TBS), and incubated overnight at 4°C in blocking buffer
supplemented with a primary antibody at the manufacturer’s suggested concentration.
Membranes were subsequently washed in 1x TBS supplemented with 0.1% Tween-20
(TBST), incubated with HRP-conjugated secondary antibody, washed once more in 1x
TBST, and developed using the LumiGLO chemiluminescence reagent (Cell Signaling,
Danvers, MA). Densitometry was performed using ImageJ. Images of scanned films
were converted into histogram form via the Analyze>Gels tool. Area under the curve
was measured and normalized to the area under the corresponding β-actin curve.

2.3.8 TCF/LEF Luciferase Reporter Assay
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Cox2 KO POBs were plated at 105 cells/well in differentiation medium in 12 well
dishes. After 24 hours they were transduced with lentiviral particles using Cignal Lenti
TCF/LEF luciferase reporter (Qiagen, Valencia, CA) and Cignal Lenti Renilla luciferase
control kits. Twenty four hours after transduction, medium was changed to
differentiation medium. Forty eight hours after transduction, cells were treated with
recombinant human SAA (10 μg/mL) or WT CM or KO CM 1 hour prior to treatment with
vehicle or PTH (10 nM) for 6 hours. Dual Luciferase assay was performed using Lumat
LB 9507 (Berthold Technologies, Oak Ridge, TN). Promoter activity values are
expressed as arbitrary units after normalization to the Renilla reporter activity.
Experiments were done in triplicate for each group.

2.3.9 Real-time (quantitative) PCR Analysis
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol: 2-5 µg of total RNA was DNase treated (Ambion, Inc., Austin,
TX) and subsequently converted to cDNA using the high capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). Quantitative PCR was performed in 96-well
plates using the Assays-on-Demand Gene Expression TaqMan primers (Applied
Biosystems, Foster City, CA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as the endogenous control gene. Samples were amplified in duplicate and
primers were checked for equal efficiency amplification over a range of target gene
concentrations. The Applied Biosystems ABI Prism 7300 Sequence detection
instrument was used to amplify a PCR reaction mixture comprised of 2x TaqMan
Universal PCR Master Mix, 20x Assays-on-Demand Gene Expression Assay Mix and
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50 ng of cDNA in a total volume of 20 µL/well at universal thermal cycling parameters.
Data analysis was performed using either comparative CT (ΔΔCT) or relative standard
curve methods

2.3.10 Statistics
All data are presented as means ± standard error of the mean (SEM). Statistical
analysis was performed using GraphPad Prism for Microsoft Windows, Version 5.04.
To compare results from experiments involving two independent variables, we used
two-way ANOVA, followed by the Bonferroni pairwise multiple comparison post-test. If
data were not normally distributed, a log10 transform was performed prior to ANOVA.

2.4. Results
2.4.1 WT CM abrogated PTH-stimulated cAMP production
We observed a Cox2-dependent inhibition of PTH’s osteogenic and anabolic
actions both in vitro and in vivo (69, 70). In cultures of bone marrow stromal cells
(BMSCs), which contain both mesenchymal and hematopoietic lineages, PTH only
stimulated osteoblast differentiation if Cox2-produced PGE2 was absent or if the
interaction of Rankl with its receptor Rank was blocked by OPG

(70).

We also showed

that the combination of Cox2-produced PGE2 and Rankl caused BMMs to secrete a
factor that inhibited PTH-stimulated osteoblast differentiation (70). The required PGE2
could be produced either by the PTH induction of Cox2 in osteoblasts or by the Rankl
induction of Cox2 in BMMs (70). By co-culturing CM from Rankl-treated WT BMMs with
POBs, we can model the inhibitory effect seen in PTH-treated BMSC cultures. We used
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POBs from Cox2 KO mice to eliminate the possibility of inducing additional Cox2/PGE 2
in POBs with PTH or serum, which might affect osteoblastic differentiation. Even though
POBs are washed multiple times during their collection, there can still be some
hematopoietic cells remaining that can differentiate into osteoclast-like cells (70). Hence,
we treated the POBs with OPG to block Rankl in the CM or Rankl induced by PTH in
the POBs from interacting with its receptor Rank on hematopoietic cells. We have
previously shown that OPG does not affect PTH-stimulated osteoblast differentiation (70).
In Figure 2A we compare the effects of no CM, WT CM and Cox2 KO CM on PTHstimulated differentiation as measured by alkaline phosphatase (Alp) mRNA expression
at 14 days of culture. Consistent with previous results, there was no difference in Alp
expression among groups of vehicle-treated POBs. PTH-stimulated Alp expression was
inhibited by WT CM but not by normal differentiation medium or Cox2 KO CM. Because
there was no difference in effects between normal differentiation medium and Cox2 KO
CM, we only compared WT and KO CM in future experiments. PTH also stimulated
expression of Runx2, an early marker of osteoblast differentiation, only in the presence
of Cox2 KO CM (Fig. 2B). Because PTH has much of its downstream signaling via the
cAMP/PKA pathway (12, 53, 90, 91), we examined the effect of WT CM on cAMP produced
in response to PTH and to forskolin, a direct adenylyl cyclase (AC) agonist (Fig. 2C).
Forskolin and PTH markedly stimulated cAMP production in the presence of Cox2 KO
CM. WT CM blocked the stimulation of cAMP by both the PTH and forskolin. Similarly,
PTH stimulated the expression of c-Fos, an early response gene mediated by the cAMP
pathway (92), in POBs treated with KO, not WT, CM (Fig. 2D). Thus, WT CM blocked
PTH-stimulated cAMP production and signaling.
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2.4.2 WT CM blocked PTH phosphorylation of β-catenin
Previous studies identified a cAMP/PKA-dependent pathway that stimulates βcatenin signaling (36, 37, 89). The hallmark of this pathway is the phosphorylation of βcatenin at Ser552 and/or Ser675 by PKA. We compared the effects of WT and Cox2 KO
CM on PTH-stimulated phosphorylation at these two sites. PTH stimulated
phosphorylation at both sites only in the presence of KO CM (Fig 3A). Phosphorylation
was observed as early as 15 minutes of treatment and was sustained at 45 minutes of
treatment (Fig. 3A). PTH caused a 3- and 2-fold increase of Ser552 and Ser675
phosphorylation, respectively, at 15 min (Fig. 3B-C), but did not increase total β-catenin
levels (Fig. 3D).
To determine if this effect was dependent on PKA, we treated with H89, a PKA
inhibitor (Fig. 4). H89 had no effect on POBs treated with WT CM. In POBs co-cultured
with KO CM, the PTH-stimulated increase in Ser552 and Ser675 phosphorylation was
abrogated by the presence of H89 (Fig. 4A). Although H89 is a selective inhibitor of
PKA, it has been reported to have off-target effects on PKC (93). In order to rule out
involvement of PKC, we treated with a specific PKC inhibitor, GF109203X, at a dose
previously shown to inhibit the effects of phorbol myristate acetate

(94).

GF109203X had

no effect on PTH stimulation of β-catenin phosphorylation (Fig. 4B).
To examine whether or not β-catenin destruction was being affected by PTH
treatment we examined both total levels of β-catenin as well as the GSK3β-stimulated
phosphorylation sites that mark β-catenin for ubiquitination and destruction
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(Ser33/37/Thr41). There was no effect of PTH on levels of total β-catenin or β-catenin
marked for destruction in the presence of KO CM (Fig. 4E-F).

2.4.3 WT CM or SAA blocked PTH stimulated β-catenin transcriptional activity
β-catenin signals by binding to TCF/LEF transcription factors in the nucleus, which
leads to the transcription and expression of Wnt-responsive genes (95). Although
previous reports have differed on whether or not phosphorylation of β-catenin at Ser552
and Ser675 results in an increase in stability and nuclear translocation, they have
generally reported increased transcriptional activity of β-catenin (36, 37, 41, 89). To
examine effects on transcriptional activity in POBs, we measured activity of a TCF/LEFinducible firefly luciferase reporter normalized to activity of a constitutively active renilla
luciferase construct. We compared the effects on PTH-stimulated TCF/LEF activity of
WT CM and SAA, a human analog of Saa3, which we have proposed to be the specific
factor in the WT CM that inhibits the effects of PTH (71).
LiCl, which can activate Wnt signaling by inhibiting GSK3β, stimulated luciferase
activity that was not inhibited by SAA (Fig. 5A). In the experiments shown in Fig. 5B-C,
6 hours of treatment with PTH induced a 4- to 5-fold increase in TCF/LEF activity in
POBs treated with no CM or with Cox2 KO CM. Both WT CM and SAA abrogated the
PTH stimulation of luciferase activity. Hence, WT CM and SAA have similar inhibitory
effects. These data suggest that SAA does not inhibit a Wnt signaling pathway acting
via GSK3β but does inhibit the PTH stimulation of β-catenin activity mediated by
phosphorylation of β-catenin at Ser552 and Ser675.
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2.4.4 WT CM blocked the PTH regulation of genes involved in Wnt signaling
To examine effects of the inhibitory CM on the PTH regulation of specific genes
known to be involved in Wnt signaling, we treated POBs for 3 hours with PTH and
compared responses in WT or Cox2 KO CM. Several Wnts--Wnt4, Wnt7b, and
Wnt10b--were increased in expression only in KO CM treated groups (Fig. 6). Wnt4
has been associated with the anabolic effects of PTH and found to be stimulatory for
osteoblastogenesis and bone formation (85, 96). Expression of Wnt7b can be induced by
PTH, has been shown to increase with osteoblastic differentiation and to increase bone
mass as well as osteoblast number in vivo (97). Wnt10b is an important factor in
coupling the actions of osteoblasts and osteoclasts, while also being able to enhance
commitment to the osteoblastic lineage (98, 99). In contrast, the expression of Wnt5a,
reported to antagonize canonical Wnt signaling by stimulating destruction of β-catenin
via GSK3β (100), was unaffected by PTH treatment in both WT and KO CM treated
groups (Fig. 6). We were unable to detect Wnt3A mRNA (data not shown). Expression
of Nfatc1, shown to be important for non-canonical Wnt signaling (101) and for the PTH
induction of Cox2 (102), was markedly induced by PTH only in KO CM. Expression of cMyc, a Wnt target gene in colorectal cancer (103), was also increased by PTH only in KO
CM.
In contrast to genes that positively regulate Wnt signaling, the expression of genes
thought to inhibit Wnt signaling was inhibited by PTH in Cox2 KO CM (Fig. 6). Genes
coding for the canonical Wnt signaling inhibitors Sfrp1 and Dkk1, which inhibit Wnt
agonist interaction with Frizzled and Lrp5/6, respectively, were undetectable in cultures
treated with PTH in the presence of KO CM. Hence, the inhibitory CM blocked the PTH
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stimulation of multiple genes that may enhance osteogenic or anabolic responses and
the PTH inhibition of several genes that inhibit these Wnt signaling.

2.5. Discussion
Our results suggest a prominent role for the β-catenin sites Ser552 and Ser675 in
mediating PTH-stimulated β-catenin transcriptional activity and Wnt-related gene
expression. We demonstrated that a novel inhibitor, produced by Cox2-expressing
BMMs and shown to block PTH-stimulated osteoblast differentiation in vitro (70), blocked
PTH-stimulated cAMP production and PKA phosphorylation at these sites, along with
subsequent β-catenin transcriptional activity. Although PTH can activate both PKA and
PKC signaling pathways, our observations strongly suggest that the direct effects of
PTH on β-catenin signaling and osteoblast differentiation occur via Gαs/cAMP-initiated
pathways as previously reported (12, 85).
A number of studies have reported that PTH promotes increased β-catenin
transcriptional activity but the specific steps by which this occurs are still not clear. PTH
has been shown to be a potent inhibitor of canonical Wnt antagonists, including Dkk1,
Sost, and Sfrp, which can lead to enhanced Wnt signaling and stabilization of β-catenin
(14, 104-106),

and to increase the expression of Wnt agonists

(107).

An early study in rat

osteosarcoma UMR-106 cells reported that PTH acted via the canonical Wnt signaling
pathway to increase Lrp6 and Fzd-1 expression, decrease Dkk1 expression, and
increase β-catenin levels and activity and that these effects were dependent on cAMP
signaling (39). However, PTH was also reported to activate -catenin signaling by
directly recruiting dishevelled independently of Wnt or Lrp5/6 in UMR cells
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(16)

and by

directly inactivating GSK-3 in human osteosarcoma Saos-2 cells (18). Another study in
UMR cells and in vivo showed that PTH stabilized -catenin in osteoblasts by activating
binding of its receptor PTH1R to Lrp6 and by activating PKA to phosphorylate Lrp6
41, 47).

(37,

One other group has linked PTH to phosphorylation of Ser675 on β-catenin (89).

They used bone marrow stromal cells and MC3T3-E1 cells and found that PTH
stimulated increased -catenin activity but did not increase total -catenin levels. In our
murine POB model, we did not find any evidence of GSK-3 mediated phosphorylation
of β-catenin at Ser33/37/Thr41 nor did we observe any increases in total -catenin,
suggesting that PTH acted to increase the signaling efficiency of the current population
of β-catenin rather than preventing its destruction. Our results agree with Taurin et al.
who reported that PKA phosphorylation of β-catenin at Ser552 and Ser675 increased βcatenin transcriptional activity, while leaving the destruction markers and complex
unaffected (37, 104).
Our in vitro results in POBs treated continuously with PTH are similar to our in vivo
effects in WT and Cox2 KO mice continuously infused with PTH for 12 or 21 days.
Infused PTH was anabolic for bone only in Cox2 KO mice, not in WT mice. PTH
infusion increased expression in tibiae of Wnt4 and Wnt10b and decreased expression
of Sfrp1, Dkk1 and Sost only in Cox2 KO mice. Expression of Wnt3a was undetectable
in our in vitro studies and was not regulated by PTH in either WT or KO mice in the
infusion studies. Wnt3a is frequently used as an exogenous agent to induce canonical
Wnt signaling. Our data suggest that other Wnts (Wnt4, Wnt7b, and Wnt10) are more
likely to be involved in the direct osteogenic/anabolic effects of PTH. One interesting
possibility is that the PTH-induced phosphorylation of β-catenin at Ser552 and Ser675
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could be priming osteoblasts for subsequent Wnt-signaling to take place by increasing
expression of these Wnts and decreasing the expression of Wnt inhibitors.
These studies highlight the potential role of the Cox2-dependent inhibitory factor for
modulating the osteogenic/anabolic actions of PTH. We have recently identified the
inhibitory factor as Saa3 (71). Saa3 can be stimulated by PTH itself. PTH induces
Cox2/PGE2 and Rankl in the osteoblast lineage, and Rankl then commits
monocyte/macrophages to the osteoclast lineage and induces more Cox2/PGE2 in
preosteoclasts, leading to the secretion of Saa3 (Fig. 7). It seems likely that this
inhibitory factor suppresses the anabolic responses to continuously elevated PTH

(69)

and may also inhibit the anabolic responses to intermittently elevated PTH in vivo (31, 69).
Saa3 is an acute phase protein, generally considered to be associated with acute and
chronic inflammation, and its levels can be increased many fold under inflammatory
circumstances (79). Hence, Saa3 might be an important means by which inflammatory
agents suppress PTH-stimulated anabolic actions and cause bone loss and, therefore,
Saa3 might be implicated in the bone loss associated with aging and chronic
inflammation.
Our results suggest that the suppression of the osteogenic/anabolic responses to
PTH, associated with Cox2 expression, is due to the inhibition of PTH/cAMP/PKA
stimulated -catenin signaling by Rankl-stimulated BMMs. Thus, the
osteogenic/anabolic effects of PTH might be enhanced by interrupting the production of
the Cox2-mediated induction of Saa3.
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Fig. 2. CM from WT BMMs inhibited PTH-stimulated osteoblast differentiation and
cAMP production. (A) Cox2 KO POBs were cultured for 14 days in the presence of no
CM (differentiation media), WT CM, or Cox2 KO CM and either vehicle or PTH (10 nM).
On day 14 of culture, Alp mRNA expression was measured by qRT-PCR. (B) On day 5
of culture, Cox2 KO POBs were treated with vehicle or PTH (10 nM) for 3 hours. Runx2
expression was measured by qRT-PCR. (C) On day 5 of culture, Cox2 KO POBs were
treated with vehicle or PTH (10 nM) for 15 minutes. cAMP was measured by ELISA. (D)
On day 5 of culture, Cox2 KO POBs were treated with vehicle or PTH (10 nM) for 3
hours. c-Fos expression was measured by qRT-PCR. Bars represent mean ± SEM,
n=3. aSignificant effect of PTH, p<0.01. bSignificant difference compared to WT CM,
p<0.01.
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Fig. 3. PTH increased phosphorylation of β-catenin at ser552 and ser675 in the
absence of WT CM. Cox2 KO POBs were treated with vehicle or PTH (10 nM) on day 5
of culture and Western analysis was performed. (A) Time course examining effects of
PTH on β-catenin phosphorylation. (B-E) Densitometry of bands was performed and
normalized to β-actin. Vehicle-treated WT CM was set to 1. Bars represent means ±
SEM, n=4. aSignificant effect of PTH, p<0.01; bp<0.05. cSignificant difference
compared to WT CM, p<0.01; dp>0.05.
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34

Wnt5a mRNA

Wnt4 mRNA
40
30
20
3
2
1
0

a,c

Veh
PTH

1.5
1.0

15
10
1.5
1.0
0.5
0.0

30
d

0.5
0.0
WT CM

KO CM

a,c

Veh
PTH

WT CM

KO CM

20
3
2
1
0

c-Myc mRNA

Nfatc1 mRNA
20

Veh
PTH

2.0
1.5

Veh
PTH

b,c

Wnt10b mRNA

Wnt7b mRNA
40

15

Veh
PTH

a,c
10

1.0

a,c

5
d
0
WT CM

KO CM

Sfrp1 mRNA
1.5

Veh
PTH

Veh
PTH

WT CM

KO CM

Dkk1 mRNA
1.5

c
1.0

Veh
PTH

c

1.0
0.5

0.5
0.0
WT CM

KO CM

WT CM

KO CM

0.0

0.5
WT CM

Und
KO CM

0.0

Und
WT CM

KO CM

Fig. 6. PTH regulated expression of genes associated with Wnt signaling only in
the absence of WT CM. Cox2 KO POBs were treated with vehicle or 10 nM PTH for 3
hours on day 5 of culture. mRNA was measured by qRT-PCR. Genes whose
expression was undetectable are marked Und. Bars are means ± SEM, n=3.
aSignificant

effect of PTH, p<0.01; bp<0.05. cSignificant effect compared to WT CM,

p<0.01; dp<0.05.
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Fig. 7. Proposed means by which PTH inhibits its own osteogenic/anabolic
actions. PTH stimulates Rankl and Cox2/PGE2 in osteoblast (OB) lineage cells. Rankl
acts on osteoclast (OC) lineage cells to commit them to become osteoclasts and to
stimulate more Cox2/PGE2. The combination of Rankl and PGE2 cause cells committed
to become osteoclasts to secrete Saa3. In the presence of Saa3, PTH-stimulated cAMP
production is abrogated, preventing subsequent PKA activation and β-catenin signaling.
When PTH is unable to initiate this negative feedback pathway, either by absence of
osteoclasts or Cox2, β-catenin is phosphorylated at Ser552 and Ser675 and can
stimulate gene transcription associated with osteoblastic differentiation.
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3. PTH Stimulation of RANKL in Primary Osteoblasts Is Independent of PTHStimulated cAMP.
3.1 Abstract
Parathyroid hormone (PTH) can stimulate both bone formation and resorption. When
PTH is given continuously, resorption is greater than formation and bone is lost. We
showed that the osteogenic actions of continuous PTH in vitro are suppressed by a
factor that blocks PTH-stimulated cAMP production in osteoblastic cells. The production
of this factor is dependent on the expression of cyclooxygenase 2 (Cox2), the major
enzyme regulating prostaglandin production. When we treated wild type (WT) and
Cox2 knockout (KO) mice with PTH infusion for 12-21 days, we found that anabolic
actions of PTH were suppressed in WT, but not KO mice. However, the PTH
stimulation of bone resorption was the same in both WT and KO mice. We have
identified the inhibitory factor in vitro as serum amyloid A 3 (Saa3) and shown that Saa3
is secreted by bone marrow macrophages (BMMs) treated with RANKL. In this study we
use the conditioned media (CM) from RANKL-treated WT BMMs or a recombinant,
human-homolog of murine Saa3 (SAA) to study the involvement of cAMP-activated
signaling in the PTH induction of Rankl. We cultured primary osteoblasts (POBs) from
neonatal calvaria to confluence (5 days), treated with PTH (10 nM) in the presence or
absence of CM or SAA (10 µg/mL) for 3 h and measured gene expression by qPCR.
SAA concentration was determined by dose response as measured by cAMP signaling
inhibition. As expected, both CM and SAA blocked the PTH-stimulated gene
expression of cAMP-regulated receptor activity modifying protein 3 (Ramp3). However,
PTH stimulated Rankl expression was not decreased by CM or SAA. The protein kinase
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A (PKA) inhibitor, H-89, blocked PTH-stimulated Ramp3 expression but had no effect
on PTH-stimulated Rankl expression. PTH has also been shown to activate the protein
kinase C (PKC) pathway, which subsequently signals via extracellular-signal-regulated
kinases (ERKs). The PKC inhibitor GF109203X and the ERK inhibitor PD98059 both
blocked PTH-stimulated Rankl expression but did not decrease PTH-stimulated Ramp3.
The calcium chelation agent BAPTA also blocked PTH-stimulated Rankl expression. In
conclusion, our results indicate that PTH-stimulated Rankl in POBs is independent of
cAMP signaling and is likely to depend upon the PKC pathway. These data support our
PTH infusion study, which indicated that the anabolic and catabolic effects of PTH occur
via different signaling pathways.

3.2 Introduction
Receptor activator of nuclear kappa-b ligand (RANKL) is an important factor in bone
metabolism, mediating the crosstalk between osteoblast and osteoclast populations in
order to maintain homeostasis. While RANKL is expressed by a multitude of cells
including dendritic and mammary epithelial cells (108), its expression in the osteoblast
lineage acts to stimulate the RANK receptor on osteoclast precursors to cause
differentiation and activate resorption (109). In order to counteract this resorption
response, osteoblasts can also secrete osteoprotegerin (OPG) which acts as a decoy
receptor for RANKL thereby competitively inhibiting the osteoclast response.
Parathyroid hormone (PTH) enacts its effects on resorption by stimulating RANKL
expression in the osteoblast lineage (110-112). Previous results have suggested that PTH
acts through the cAMP/PKA signaling pathway to stimulate RANKL expression in
osteoblasts (52, 53, 113). Our lab has recently discovered a factor secreted by osteoclast
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precursors in response to prostaglandin E2 (PGE2) that acts as a potent cAMP inhibitor
in osteoblasts (69, 70). This factor was identified as serum amyloid a3 (Saa3)

(71).

We

have developed an in vitro model by which we can introduce Saa3 into culture via
conditioned medium (CM) collected from cultures of bone marrow macrophages
(BMMs) stimulated down the osteoclast lineage by treatment of RANKL and M-CSF (70).
In this study we use this model to determine the effects of the cAMP inhibitor, Saa3,
upon PTH stimulation of RANKL in primary osteoblasts (POBs). By doing so we hope
to determine whether cAMP signaling is required for PTH-stimulation of RANKL.

3.3 Materials and Methods
3.3.1 Materials
Bovine PTH (bPTH; 1-34) was obtained from Sigma-Aldrich (St. Louis, MO). PGE2 was
obtained from Cayman Chemical Company (Ann Arbor, MI). FSK (cAMP agonist), H-89
(PKA inhibitor), GF109203X (PKC inhibitor), PD98059 (MEK/ERK inhibitor), and BAPTA
(Calcium chelation agent) were obtained from Enzo Life Sciences (Farmingdale, NY).
PD 0325901 (MEK/ERK inhibitor) was obtained from Sigma-Aldrich (St. Louis, MO).
Human recombinant SAA (Apo-SAA), which corresponds to human Apo-SAA1α, except for the
presence of an N-terminal methionine and two substituted residues present in Apo-SAA2β, was
purchased from PeproTech (Rocky Hill, NJ). Antibody for Actin C-11 (sc-1615) was

obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Total MEK (9122), total
ERK (9107), p-MEK (9121), and p-ERK (9101) antibodies were obtained from Cell
Signaling Technology (Danvers, MA).

3.3.2 Animals
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Mice that produce non-functional Cox2 protein, due to disruption of Ptgs2 in a
C57BL/6, 129SV background, which we call Cox2 KO mice, were the gift of Scott
Morham (30). Cox2 KO mice were backcrossed into the outbred CD-1 background (31).
Following 20 generations of backcrossing, the Cox2 KO mice no longer developed
either renal failure or female infertility (31). Maintenance colonies heterozygous for the
Cox2 gene disruption were refreshed twice a year with WT mice from Jackson
Laboratory (Bar Harbor, ME) to prevent genetic drift. Mice are genotyped as described
previously, and experimental mice are bred by WT x WT or KO x KO mating

(31).

Animal

studies were performed in compliance with protocols approved by the Animal Care and
Use Committee of UConn Health.

3.3.3 Cell Culture
All cell cultures were grown in humidified incubation conditions of 5% CO2 at 37°C.
Basic medium was 10% heat inactivated fetal calf serum (HIFCS), 100 U/mL penicillin,
and 50 µg/mL streptomycin in α-MEM (Invitrogen, Carlsbad, CA). Osteoblast
differentiation medium was basic media supplemented with 50 µg/mL
phosphoascorbate. Treatment vehicles were the following: 0.001 N hydrochloric acidacidified 0.1% bovine serum albumin (BSA) in 1x phosphate buffered saline (PBS) for
PTH; 0.1% BSA in 1x PBS for osteoprotegerin (OPG), macrophage colony stimulating
factor (M-CSF), and receptor activator of nuclear factor κ-B ligand (Rankl); and dimethyl
sulfoxide (DMSO) for isobutyl methyl xanthine (IBMX), H-89, GF109203X, and forskolin.

3.3.4 Primary Osteoblasts (POBs)
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POBs were harvested from calvariae of neonatal mice. Sutures were removed and
the calvariae were minced, washed multiple times with 1x PBS, and subsequently
digested with 0.5 mg/mL collagenase P (Roche Diagnostics, Indianapolis, IN)
solubilized in 1 mL trypsin/EDTA and 4 mL PBS at 37°C. Four 10 minute digests were
performed followed by a fifth and final digest for 90 minutes. After each digest the
reaction was halted by the addition of 10% HIFCS. Cells from digests 2-5 were
collected, filtered through a Nitex membrane (Millipore, Bedford, MA), and plated at a
density of 50,000 cells/well in 6-well cell culture plates in differentiation medium.
Medium was changed every three days. We used only freshly plated cells for all
experiments.

3.3.5 Culture of Conditioned Medium (CM) with POBs
CM was collected from BMM cultures, centrifuged for 5 minutes at 800 rpm at 4°C to
remove debris and frozen for later use. BMMs were cultured following the Faccio
protocol: http://www.orthoresearch.wustl.edu/content/Laboratories/2978/RobertaFaccio/Faccio-Lab/Protocols.aspx. BMMs were obtained from 8 week old mice

. In

brief, nucleated bone marrow cells were plated in 150 mm petri dishes (Fisher Scientific,
Pittsburgh, PA) at a density of 1 x 107 cells/dish in basic media, supplemented with 100
ng/mL M-CSF. Cultures were expanded twice for three days each. Following
expansion, BMMs were re-plated in 12-well cell culture plates at a density of 6 x 104
cells/well in basic media and treated with M-CSF and Rankl (both at 30 ng/mL). CM was
collected after 3 days of culture, a day before tartrate resistant acid phosphatase
positive multinucleated cells formed in the BMM cultures. CM was added to Cox2 KO
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POBs 2 hours before agonist treatment at a concentration of 3 parts CM to 1 part
differentiation media. The only exception was for the study of differentiation, where
treatments with agonists and CM were begun at the time of plating and continued for
the entire 14 day period. Unless noted otherwise, all cultures were treated with 50
ng/mL OPG to prevent Rankl in the CM or PTH-stimulated Rankl in the POBs from
inducing any remaining hematopoietic cells in the POB cultures from becoming
osteoclasts and making more of the inhibitory factor (70).

3.3.6 Real-time (quantitative) PCR Analysis
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol: 2-5 µg of total RNA was DNase treated (Ambion, Inc., Austin,
TX) and subsequently converted to cDNA using the high capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). Quantitative PCR was performed in 96-well
plates using the Assays-on-Demand Gene Expression TaqMan primers (Applied
Biosystems, Foster City, CA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as the endogenous control gene. Samples were amplified in duplicate and
primers were checked for equal efficiency amplification over a range of target gene
concentrations. The Applied Biosystems ABI Prism 7300 Sequence detection
instrument was used to amplify a PCR reaction mixture comprised of 2x TaqMan
Universal PCR Master Mix, 20x Assays-on-Demand Gene Expression Assay Mix and
50 ng of cDNA in a total volume of 20 µL/well at universal thermal cycling parameters.
Data analysis was performed using either comparative CT (ΔΔCT) or relative standard
curve methods
3.3.7 Western Blotting
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Proteins were extracted from culture by the addition of lysis buffer (2% SDS, 10 % glycerol,
62 mM Tris, pH: 6.85) and quantified using the BCA protein assay kit (Pierce, Rockford, IL).
10% SDS –PAGE was used to separate 15 µg of total protein, prior to transfer onto a
nitrocellulose membrane. Membranes were washed with 1x Tris-buffered saline (TBS, pH: 7.6),
blocked in blocking buffer (0.1% Tween-20, 5% (w/v) non-fat dry milk, 1x TBS), and incubated
overnight at 4°C in blocking buffer supplemented with a primary antibody at the manufacturer’s
suggested concentration. Membranes were subsequently washed in 1x TBS supplemented
with 0.1% Tween-20 (TBST), incubated with HRP-conjugated secondary antibody, washed once
more in 1x TBST, and developed using the LumiGLO chemiluminescence reagent (Cell
Signaling, Danvers, MA). Densitometry was performed using ImageJ. Images of scanned films
were converted into histogram form via the Analyze>Gels tool. Area under the curve was
measured and normalized to the area under the corresponding β-actin curve.

3.3.8 Statistics
All data are presented as means ± standard error of the mean (SEM). Statistical analysis
was performed using GraphPad Prism for Microsoft Windows, Version 5.04. To compare
results from experiments involving two independent variables, we used two-way ANOVA,
followed by the Bonferroni pairwise multiple comparison post-test. If data were not normally
distributed, a log10 transform was performed prior to ANOVA.

3.4 Results
3.4.1 PTH stimulates RANKL in POBs in the absence of cAMP signaling
In order to determine the effects of Saa3 on PTH stimulation of RANKL
expression we examined both RANKL and Ramp3 mRNA expression. Ramp3 is a
cAMP response gene used to indirectly measure levels of cAMP/PKA signaling. We
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observed that in cultures pretreated with either wild type conditioned media (WT CM)
(Fig. 8a) or exogenous recombinant human serum amyloid a (SAA) (Fig. 8b) that PTH
was unable to stimulate cAMP signaling as measured by Ramp3 expression.
Unexpectedly, we found that despite the inability of PTH to stimulate cAMP signaling in
the presence of SAA, PTH was able to stimulate a robust RANKL response comparable
to that seen in the SAA-free group (Fig. 8c).

3.4.2 PTH stimulates RANKL expression through the PKC pathway
In light of our results suggesting that PTH acts to increase RANKL expression
independently of cAMP/PKA signaling, we then began investigating other pathways that
may be involved. While PTH is known to signal through its G-protein coupled receptor
to stimulate PKA signaling through the production of cAMP via Gαs stimulation of
adenylate cyclase, it can also signal through PKC. Current thought is that PTH acts
through Gαq to activate phospholipase C, causing the production of inositol triphosphate
(IP3) and subsequent Ca2+ mobilization to activate PKC (11, 12). It is thought that once
activated, PKC acts through the MEK/ERK pathway to affect gene transcription

(60).

Other studies have also suggested that, while not directly linked to PTH, the PKC
agonist, PMA, and the ionophore, ionomycin, can both stimulate RANKL expression

(58).

Considering these findings regarding the PKC pathway and our own data suggesting
that PTH may act independently of the cAMP/PKA pathway to stimulate RANKL
expression, we challenged our system with a battery of inhibitors in order to dissect the
role of Ca2+, PKC, and ERK in this process. We found that PTH was unable to
stimulate RANKL mRNA expression in the presence of the PKC inhibitor, GF109203X,
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the ERK inhibitor, PD98059, and the calcium chelation agent, BAPTA (Fig. 9a).
However, RANKL expression remained intact as compared to vehicle when our system
was challenged with the PKA inhibitor, H89 (Fig. 9a). In order to confirm that this
inhibition occurred in the presence of robust cAMP signaling, we observed Ramp3
expression and only found its inhibition in the H89 pretreated group (Fig. 9b). This
complements our previous results where PTH was able to stimulate RANKL in the
absence of cAMP/PKA signaling, we now see that PTH’s ability to stimulate RANKL
expression can be inhibited despite robust cAMP/PKA signaling. Recent findings have
suggested that PD98059 has off-target effects on intracellular Ca2+ (114). To address
this possibility we repeated our experiment with the inclusion of another inhibitor of
MEK/ERK signaling, PD325901, which does not exhibit these off-target effects. Our
results show that both inhibitors of MEK/ERK signaling shut down PTH stimulation of
RANKL expression, confirming the involvement of the MEK/ERK portion of the pathway
(Fig. 9c).
It was then of interest to confirm our mRNA results with western blot. We
examined the phosphorylation states of MEK and ERK to determine activation of the
pathway in response to PTH, in the presence of either WT CM or KO CM. In the
presence of WT CM, PTH was unable to increase phosphorylation of either MEK or
ERK (Fig. 10a). Further, total levels of both proteins appeared to be decreased in
response to PTH in the WT CM pretreated groups (Fig. 10a). No effect of PTH upon
either the simulation or inhibition or ERK signaling was evident in KO CM pretreated
cultures (Fig. 10a). Similarly, neither an increase nor decrease of MEK/ERK signaling
was observed following out to three hours of PTH treatment (Fig. 10b).
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3.5 Discussion
Our results represent the first to link PTH-stimulated PKC signaling to RANKL
gene expression in primary osteoblasts. We hypothesize from our results that PTH
activates PKC via increases in intracellular Ca2+ and causes subsequent MEK/ERK
signaling to stimulate RANKL gene expression. Although our western blot results were
inconclusive regarding MEK/ERK stimulation by PTH, these results cannot speak to a
change in localization of MEK/ERK or other more nuanced effects. Future studies
would do well to perform dose response experiments with the signaling inhibitors used
herein to confirm the level of involvement of each Ca2+, PKC, and MEK/ERK.
Additionally, the MEK/ERK signal may be more transient than our experiments were
designed to detect and shorter time points may need to be investigated.
Apart from our results, contemporaneous studies have implicated the actions of
PKC to stimulate RANKL induction of osteoclastogenesis. Specifically, RANKLstimulated PKCβ can inhibit GSK3β to allow for NFATc1 translocation to the nucleus to
support differentiation and activation of osteoclasts from cultures of BMMs

(68).

However, our results showing that RANKL induction is dependent on PKC siglaing may
shine new light and urge for caution when manipulating the PKC pathway in vivo or in
mixed in vitro culture. Then a compounding effect may not be considered whereby the
PKC inhibitor prevents PKC from stimulating RANKL expression by osteoblasts and
also prevents RANKL stimulation of PKC mediated osteoclastogenesis within
osteoclasts.
Inhibition of the PKC pathway may then represent a novel target for treating bone
diseases whose basis lies in overactive resorption. Our data suggest that the inclusion
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of a PKC inhibitor alongside continuous PTH treatment not only proves an interesting
study but one that may prevent the deleterious catabolic effects associated with
continuous infusion.
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Fig. 8. Inhibition of cAMP signaling does not prevent PTH stimulation of RANKL
expression. On day 5 of culture, Cox-2 KO POBs were treated with vehicle or PTH (10
nM) for 3 hours following 2 hour pretreatment with WT or KO CM or Saa. mRNA was
then isolated and qRT-PCR was performed. Bars represent mean ± SEM, n=3.
a
Significant effect compared to WT CM or SAA, p<0.01. bSignificant effect of PTH, p<0.01
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Fig. 9. PTH stimulation of RANKL is dependent on calcium/PKC/ERK signaling.
On day 5 of culture, WT POBs were treated with vehicle or PTH (10 nM) for 3 hours
following 2 hour pretreatment with H89: 30 μM, GF109203X: 0.6 μM, PD98059: 50 μM,
PD0325901: 50 μM or BAPTA 50 μM. mRNA was then isolated and qRT-PCR was
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western blot was performed.
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4. Summary and Future Directions
In this study we showed that in the absence of Saa3, PTH stimulates
phosphorylation of β-catenin at serines 552 and 675 which cause an increase in
transcriptional activation of TCF/LEF and subsequent expression of Wnt target genes.
Further, we observed that PTH can stimulate expression of RANKL independent of
cAMP/PKA signaling in osteoblasts. The alternative pathway by which PTH causes
RANKL expression in these cultures seems to be through Ca2+/PKC. Together these
results point to a model by which PTH acts anabolically on bone metabolism via
cAMP/PKA and catabolically via Ca2+/PKC. However, due to the Saa3 negative
feedback loop the anabolic effects, specifically those affecting phosphorylation of βcatenin, are muted in basal conditions. Although not exhaustive, our results posit no
parallel negative feedback loop by which PTH can silence its own catabolic effects.
These observations help explain why PTH acts largely catabolically in vivo.
Still to be determined is the contribution of this PTH/β-catenin pathway to
osteoblast differentiation and bone formation in general. First steps to quantify this
contribution may include determining whether or not PTH stimulation of osteoblasts in
the absence of Saa3 primes subsequent Wnt signaling. Our results indicate that
several Wnt agonists experience a rapid upregulation in gene expression, while Wnt
antagonists experience a downregulation in response to PTH treatment in the absence
of Saa3. Observations at later time points may reveal the downstream effects of this
gene expression or indeed if cultures are more sensitive to exogenous Wnt signaling
post PTH treatment. In order to determine the importance of phosphorylation of serines
552 and 675 in β-catenin signaling, and bone biology as a whole, the incorporation of
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alanine substitutions at these sites in an in vivo model would be of interest. Previous in
vitro studies have shown that ser-to-ala substitutions at these sites abolishes the ability
of PKA to phosphorylate these sites (37). Observing how mutations at these sites affect
not only both the β-catenin and Rankl pathways in vitro and further how they affect bone
metabolism in vivo is of great interest.
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